There are several concluded or ongoing clinical trials for the use of drugs for IL-8 and IL-6 targeting, or IL-6 receptor (IL6R) targeting, in patients with different diseases, including solid tumors and metastatic cancers (NCT04347226, NCT02536469, are some examples from2). Here, CXCL8 is linked to metastatic malignant neoplasm.